GLP-1 and GIP Drugs Before Endoscopy May Raise Residual Gastric Volume Risk

Continuing to take a glucagon-like peptide-1 (GLP-1) or a GLP-1/glucose-dependent insulinotropic polypeptide (GIP) receptor agonist prior to upper endoscopy appeared to increase risk of clinically significant residual gastric volume, a randomized clinical trial found.

Authors

Publication Details

Journal
JAMA
Published
2026-04-03
DOI
https://doi.org/10.1001/jama.2026.1035
Primary Topic
Diabetes Treatment and Management
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

GLP-1 and GIP Drugs Before Endoscopy May Raise Residual Gastric Volume Risk

Samantha Anderer
JAMA
Diabetes Treatment and Management
article

GLP-1 and GIP Drugs Before Endoscopy May Raise Residual Gastric Volume Risk

Samantha Anderer
article en

Abstract

Continuing to take a glucagon-like peptide-1 (GLP-1) or a GLP-1/glucose-dependent insulinotropic polypeptide (GIP) receptor agonist prior to upper endoscopy appeared to increase risk of clinically significant residual gastric volume, a randomized clinical trial found.

JAMAVol. 335(16)
Zero hunger
Openalex Percentile: Top 29%
Diabetes Treatment and Management
DOISourceOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

GLP-1 and GIP Drugs Before Endoscopy May Raise Residual Gastric Volume Risk — Samantha Anderer · JAMA (2026) | TGRS Research Map | TGRS